TY - JOUR
T1 - Analysis of next-generation genomic data in cancer
T2 - Accomplishments and challenges
AU - Ding, Li
AU - Wendl, Michael C.
AU - Koboldt, Daniel C.
AU - Mardis, Elaine R.
N1 - Funding Information:
The authors wish to acknowledge funding from the National Institutes of Health, National Human Genome Research Institute U54 HG003079 (PI: Richard K. Wilson).
PY - 2010/10/15
Y1 - 2010/10/15
N2 - The application of next-generation sequencing technology has produced a transformation in cancer genomics, generating large data sets that can be analyzed in different ways to answer a multitude of questions about the genomic alterations associated with the disease. Analytical approaches can discover focused mutations such as substitutions and small insertion/deletions, large structural alterations and copy number events. As our capacity to produce such data for multiple cancers of the same type is improving, so are the demands to analyze multiple tumor genomes simultaneously growing. For example, pathwaybased analyses that provide the full mutational impact on cellular protein networks and correlation analyses aimed at revealing causal relationships between genomic alterations and clinical presentations are both enabled. As the repertoire of data grows to include mRNA-seq, non-coding RNA-seq and methylation for multiple genomes, our challenge will be to intelligently integrate data types and genomes to produce a coherent picture of the genetic basis of cancer.
AB - The application of next-generation sequencing technology has produced a transformation in cancer genomics, generating large data sets that can be analyzed in different ways to answer a multitude of questions about the genomic alterations associated with the disease. Analytical approaches can discover focused mutations such as substitutions and small insertion/deletions, large structural alterations and copy number events. As our capacity to produce such data for multiple cancers of the same type is improving, so are the demands to analyze multiple tumor genomes simultaneously growing. For example, pathwaybased analyses that provide the full mutational impact on cellular protein networks and correlation analyses aimed at revealing causal relationships between genomic alterations and clinical presentations are both enabled. As the repertoire of data grows to include mRNA-seq, non-coding RNA-seq and methylation for multiple genomes, our challenge will be to intelligently integrate data types and genomes to produce a coherent picture of the genetic basis of cancer.
UR - http://www.scopus.com/inward/record.url?scp=78650791604&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddq391
DO - 10.1093/hmg/ddq391
M3 - Article
C2 - 20843826
AN - SCOPUS:78650791604
SN - 0964-6906
VL - 19
SP - R188-R196
JO - Human molecular genetics
JF - Human molecular genetics
IS - R2
ER -